Champions Oncology
CSBR
35 hedge funds and large institutions have $64.1M invested in Champions Oncology in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
2.92% less ownership
Funds ownership: 49.71% → 46.78% (-2.9%)
8% less funds holding
Funds holding: 38 → 35 (-3)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
82% less capital inflows, than outflows
Capital inflows: $879K | Capital outflows: $4.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$444K |
| 2 |
BlackRock
New York
|
+$156K |
| 3 |
ACT Capital Management
Wayne,
Pennsylvania
|
+$86.5K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$71.6K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$60K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Roubaix Capital
Denver,
Colorado
|
-$3.61M |
| 2 |
Millennium Management
New York
|
-$284K |
| 3 |
Bank of New York Mellon
New York
|
-$214K |
| 4 |
Overbrook Management Corp
New York
|
-$137K |
| 5 |
Morgan Stanley
New York
|
-$131K |
CSBR Hedge Fund Activity: Q3 2021 in Review
35 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q3 2021, worth a combined $64.1M — down 6.3% from $68.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CSBR and 2 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was Millrace Asset Group, adding an estimated $444K. The largest seller was Roubaix Capital, exiting entirely with an estimated $3.61M sold.
- 35 institutional investors held Champions Oncology (CSBR) as of Q3 2021, down from 38 in Q2 2021.
- Funds reported $64.1M of Champions Oncology stock for Q3 2021, down 6.3% quarter-over-quarter.
- 2 funds opened new Champions Oncology positions in Q3 2021 and 5 closed out, a net change of -3 holders.
- The largest Champions Oncology buyer in Q3 2021 was Millrace Asset Group, an estimated $444K added.
- The largest Champions Oncology seller in Q3 2021 was Roubaix Capital, an estimated $3.61M sold.
Based on aggregated 13F filings for Q3 2021.